相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T.K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
Tina R. Watson et al.
JAMA NETWORK OPEN (2020)
Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies
Tiphaine Cholley et al.
CLINICAL GENITOURINARY CANCER (2019)
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2019)
Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Nizar M. Tannir et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Kidney Cancer, Version 2.2020 Featured Updates to the NCCN Guidelines
Robert J. Motzer et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
PMU4 WHAT IS A GOOD OR BAD NUMBER NEED TO TREAT (NNT) VALUE? A LITERATURE REVIEW
K. Azimpour et al.
VALUE IN HEALTH (2019)
Economic Burden of Renal Cell CarcinomaPart I: An Updated Review
Chun-Ru Chien et al.
PHARMACOECONOMICS (2019)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Number needed to treat (NNT) and cost of preventing an event (COPE) of PD-1/PD-L1 antibodies for previously treated advanced non-small cell lung cancer (NSCLC) patients in Brazil
Fernanda Oliveira et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Bin Wu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
COST PER RESPONSE ANALYSIS OF NIVOLUMAB VERSUS EVEROLIMUS IN THE TREATMENT OF PATIENTS PREVIOUSLY TREATED WITH ADVANCED RENAL CELL CARCINOMA - BRAZIL PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
L. Brust et al.
VALUE IN HEALTH (2017)
Renal cell carcinoma
James J. Hsieh et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Brazilian data of renal cell carcinoma in a public university hospital
Pedro Aguiar Junior et al.
INTERNATIONAL BRAZ J UROL (2016)
Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2
Anne V. Soerensen et al.
EUROPEAN UROLOGY (2015)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel Y. C. Heng et al.
LANCET ONCOLOGY (2013)
Number needed to treat is incorrect without proper time-related considerations
Daniel Suissa et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2012)
Cost-effectiveness of sunitinib in metastatic renal cell carcinoma
Timo T. Purmonen
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2011)
Current and predicted cost of metastatic renal cell carcinoma in Finland
Timo Purmonen et al.
ACTA ONCOLOGICA (2010)
Evidence-based urology in practice: number needed to treat
Rodney H. Breau et al.
BJU INTERNATIONAL (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Key principles for the improved conduct of health technology assessments for resource allocation decisions
Michael F. Drummond et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2008)
Methodological issues in the economic analysis of cancer treatments
Paul Tappenden et al.
EUROPEAN JOURNAL OF CANCER (2006)
Cost-effectiveness analysis based on the number-needed-to-treat: common sense or non-sense?
IS Kristiansen et al.
HEALTH ECONOMICS (2004)
分享论文
